Navigation Links
High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors


QuikChange XL: a highly versatile kit for site-directed mutagenesis of large plasmids

Michael Borns Peter Vaillancourt Holly Hogrefe Jeff Braman
Stratagene

The QuikChange site-directed mutagenesis kit* characteristically generates mutagenesis efficiencies exceeding 80%. We have created a new kit for mutagenesis of large plasmid templates. The QuikChange XL site-directed mutagenesis kit has been specifically formulated for mutagenesis of longer targets, and is packaged with XL10-Gold ultra competent cells**, which are optimized for the transformation of larger DNA molecules. We demonstrate the improved performance of the QuikChangeXL kit by mutagenizing a 10.1-kb retroviral vector that was otherwise difficult to mutagenize.

Site-directed mutagenesis is routinely employed in numerous research endeavors. The procedure can be laborious and time-consuming, requiring either single-stranded DNA templates1, subcloning into specialized vectors2, plasmid vectors containing unique restriction sites, and/or multiple transformations into different host strains3. In contrast, the QuikChange site-directed mutagenesis kit4 features a highly efficient procedure that is significantly streamlined when compared to other mutagenesis methods. With this kit, site-specific mutation can take place in virtually any double-stranded plasmid, eliminating the need for subcloning into M13-based bacteriophage vectors and ssDNA rescue. In addition, the kits procedure does not require specialized vectors, unique restriction sites, or multiple transformations. The protocol can be completed in just one day and generates mutagenesis efficiencies exceeding 80%.

Another important feature of the kit is the use of high-fidelity PfuTurbo DNA polymerase.*** This key component permits template DNA replication with an error rate that is significantly lower than conventional thermostable enzymes5 minimizing undesirable second-site mutations.

Improving Mutagenesis of Large Plasmids

In the new QuikChange XL kit, modifications have been made to the QuikChange method to improve the efficiency of mutagenizing large or difficult plasmid vectors. In addition, XL10-Gold ultracompetent cells have been included to ensure the highest transformation efficiencies possible (Figure 1). The transformation efficiency of XL10-Gold cells is 5-fold higher than the transformation efficiency of XL1-Blue cells employed in the standard QuikChange kit6. Moreover, XL10-Gold cells contain the Hte phenotype, which increases transformation efficiency of larger DNA plasmids.

The performance of the QuikChange XL kit is demonstrated in mutagenesis studies employing a 10.1-kb plasmid. In this study, primers were designed to repair a frameshift mutation by inserting the missing nucleotide in the open reading frame (ORF) of the Moloney Murine Leukemia Virus (MMLV) gag-pol fusion protein. QuikChange reactions were performed with components of the standard kit or the QuikChange XL kit. Electrophoresis of Dpn I-digested reaction products showed that bands of the appropriate size (10.1-kb) were only evident in reactions performed with components of the QuikChange XL kit (Figure 2, lane 1). Moreover, transformation of XL10-Gold cells with a QuikChange XL reaction produced 32 colonies. In contrast, no colonies were produced with the standard QuikChange kit (Table 1). Nine out of 10 colonies produced a plasmid with the correct base insertion, as evidenced by DNA sequence analysis, and restoration of gag-pol gene function was verified by assaying reverse transcriptase activity and production of infectious virus (data not shown).

DNA Template
(kb)

Extension Time
(minutes/kb)

Number of Transformantsa

QuikChange kit

QuikChange XL kit

10.1

1

0

32

aReactions were carried out as described in the text and kit manuals. Values represent mean number of transformants from 3 plates.

Small-to-moderately sized plasmid DNA templates can be efficiently mutagenized with either QuikChange kit4. For such targets, the QuikChange XL kit permits the use of reduced reaction times. For example, the 4.5-kb kit control was efficiently replicated with the QuikChange XL kit using 0.5 min/kb extension times rather the 2 minute/kb extension times recommended for the standard QuikChange kit (data not shown). In these experiments, the average mutation frequency for the kit control was 98%, indicating that QuikChange XL kit retains the high mutagenesis efficiency of the QuikChange site-directed mutagenesis method.

Conclusions

We have introduced the QuikChange XL site-directed mutagenesis kit to improve the efficiency of mutagenizing long or difficult-to-mutagenize plasmid DNA templates using this single day mutagenesis method. The QuikChange XL kit features components specifically designed for more efficient DNA replication and bacterial transformation, which are important when mutagenizing large templates. The QuikChange XL kit retains the simplicity and ease-of-use of the parent kit, while ensuring high-efficiency mutagenesis of a broad range of plasmid DNA templates.

REFERENCES
  1. Kunkel, T.A. (1985) Proc. Nat. Acad. Sci. USA 82: 488-492.
  2. Bohnsack, R.N. (1996) In Vitro Mutagenesis Protocols 57: 1-12.
  3. Zhu, L. (1996) In Vitro Mutagenesis Protocols 57: 13-29.
  4. Papworth, C., et al. (1996) Strategies 9: 3-4.
  5. Hogrefe, H., et al. (1997) Strategies 10: 93-96.
  6. Jerpseth, A., et al. (1997) Strategies 10: 37-38.

* U.S. Patent Nos. 5,789,166 and 5,932,419 and patents pending
** U.S. Patent Nos. 5,512,468 and 5,707,841 and patents pending
*** U.S. Patent No. 5,545,552 and 5,866,395 and 5,948,663 and patents pending


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
2. Big Blue Rodent Cell Cultures for Mutagenesis Studies
3. Randomize Gene Sequences with New PCR Mutagenesis Kit
4. PCR-Grade Nucleotides Larger Pack Sizes Now Available
5. Rapidly Synthesize Large Amounts of Capped RNA
6. Efficient Cloning and Electro-transformation of Large Eukaryotic DNA Fragments
7. Sub-Micron Gold Particles Are Superior to Larger Particles for Efficient Biolistic Transformation of Organelles and Some Cells
8. Efficiently Insert Unique Restriction Sites into Plasmid Vectors
9. Simple Purification of DNA from Plasmid Minipreps, PCR Amplifications and Agarose Gels
10. Generate High-Quality, Directional Plasmid cDNA Libraries
11. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways

Post Your Comments:
(Date:12/2/2009)... , LIBREVILLE, Gabon, December 2 /PRNewswi...rica: Everyone,s Problem and Heritage" , ...sity, 2-3 June 2010 the,Gabonese Republic is hosti...n) on the issue of safeguarding biological resourc...overnment and state leaders, ministers,scientific...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BI...s novel oral JAK2 inhibitor, SB1518, at The Americ...xposition in New Orleans. ,, Data will be prese...-escalation trial of SB1518 detailing its safety, ...PK/PD) profile in dose levels ranging from 100 to ...
(Date:12/2/2009)... , SHANGHAI, Dec. 2 /PRNewswire-Asia/ --...arkets are in turmoil and uncertainty is part of m...he pharma industry has been,relatively immune to t... a,vacation. , During the midst of the di...Johnson & Johnson inaugurated an R&D cente...
(Date:12/1/2009)..., INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-Fir...I ) today announced revenue guidance for the fourt... $57 million, as compared with $69 million for the...r 2008 results was the first of two installment pa...ed in fourth quarter 2008 results was a one-time $...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...ll forms of human cloning has been approved by the...lies and is headed for a full Assembly vote. State...ack with identical bills - SB 243 and AB 499 - tha...has drawn vigorous opposition from both the scient... ban if approved, would outlaw not only cloning fo...
..., a proposed ban on all forms of human cloning in ... embryos both for reproductive purposes and for wh...ic cloning, the making of a cloned embryo for the ...olating the bill if it were to become law would go.... , ,The bill was amended to exempt non-human clon...
...000 people who recently attended BIO 2005 in Phila...become a worldwide phenomenon but its also becomin...nds me of how rock n roll became mainstream in the... it, the launch of the Beatles on the Sunday night...re to stay. So is biotech! , ,Within the first 15 ...
Other Biology Technology:Cloning ban too broad, stem-cell researchers argue 2Cloning ban too broad, stem-cell researchers argue 3Cloning ban too broad, stem-cell researchers argue 4Biotech phenomenon becoming mainstream in world economy 2Biotech phenomenon becoming mainstream in world economy 3Biotech phenomenon becoming mainstream in world economy 4Biotech phenomenon becoming mainstream in world economy 5
(Date:12/2/2009)... HOBOKEN, NJ According to the National Institute ...iagnosed with diabetes already have some stage of ...e to the retina caused by leaky blood vessels, is ... and is one of the most feared diabetic complicati...o,ve had diabetes for 10 years or more will experi...
(Date:12/1/2009)... OptiNose is pleased to announce the publication o...gating the efficacy and tolerability of its novel,...eatment of chronic rhinosinusitis with nasal polyp...rnational and European Rhinologic Societies. , ...nic disease that can significantly reduce a patien...
(Date:12/1/2009)...available in German . , Brown adipose tissue ...s of mitochondria, miniature power stations which... they normally generate a voltage similar to that ...lar processes. However, the mitochondria of brown ... ahead all the time. The energy released when the ...
Breaking Biology News(10 mins):Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Brown fat cells make 'spare tires' shrink 2ResMed Acquires Laboratoires Narval 5240 1ResMed Acquires Laboratoires Narval 5240 2ResMed Acquires Laboratoires Narval 5240 3GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 1GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 2GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 3Mediterranean Diet May Help Prevent Depression 58895 1Mediterranean Diet May Help Prevent Depression 58895 2Mediterranean Diet May Help Prevent Depression 58895 3
...team based at Massachusetts General Hospital (MGH)...ess of RNA interference (RNAi), a powerful new res...mals. They used the RNAi process itself to find ne...hanism, which someday may help to fight human dise... and is receiving early online release on the Scie...
...University Health Center (MUHC) in Montreal is ple...ada resulting from frozen eggs. A team led by Prof...stetrics and Gynecology at McGill University and D...UHC in Montreal confirmed the birth of a healthy b...he first in-vitro fertilization (IVF) Centre in Ca...
...es Medical Institute researchers chiseling away at...etailed explanation of how the drugs, main cellula...o some of these medications. The findings are alre...re being engineered to circumvent resistance, whic...omas A. Steitz, a Howard Hughes Medical Institute ...
Other Biology News:Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3First frozen egg baby born in Canada 2First frozen egg baby born in Canada 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3
Acridine orange, hemizinc salt from Research Organics, Inc.
Sf9 Insect Cells from BD Biosciences Pharmingen
Acridine orange 10-nonyl bromide from AnaSpec
HistoScan AP Universal Goat Kit from Biomeda Corporation
Biology Products: